Recombinant proteins are an important tool for research and therapeutic applications. Therapeutic proteins have been delivered to several cell types and tissues and might be used to improve the outcome of the cell transplantation. Recombinant proteins are propagated in bacteria, which will contaminate them with the lypopolysacharide endotoxin found in the outer bacterial membrane. Endotoxin could interfere with in vitro biological assays and is the major pathological factor, which must be removed or inactivated before in vivo administration. Here we describe a one-step protocol in which the endotoxin activity on recombinant proteins is remarkably reduced by transient exposure to acidic conditions. Maximum endotoxin deactivation occurs at acidic pH below their respective isoelectric point (pI). This method does not require additional protein purification or separation of the protein from the endotoxin fraction. The endotoxin level was measured both in vitro and in vivo. For in vitro assessment we have utilized Limulus Amebocyte Lysate method for in vivo the pyrogenic test. We have tested the above-mentioned method with five different recombinant proteins, including a monoclonal antibody clone 5c8 against CD154 produced by hybridomas. More than 99% of endotoxin was deactivated in all of the proteins; the recovery of the protein after deactivation varied between maximum 72.9% and minimum 46.8%. The anti-CD154 clone 5c8 activity remained unchanged as verified by the measurement of binding capability to activated lymphocytes. Furthermore, the effectiveness of this method was not significantly altered by urea, commonly used in protein purification. This procedure provides a simple and cost-efficient way to reduce the endotoxin activity in antibodies and recombinant proteins. 
INTRODUCTION
Because endotoxin is temperature resistant, its elimination is one of the most difficult steps in the protein purification process (42) . The commonly used methods Many recombinant proteins with commercial and medical applications are produced utilizing genetically are the following. 1) The anion exchange chromatography (25) that utilizes the negative net charge of endomodified bacteria (E. coli), an expression system characterized by a quick production of highly concentrated toxin and its binding to the anion exchange resin. This method can be applied only to basic proteins that do not protein. The decontamination from endotoxin during the purification process is a prerequisite for most recombibind to anion exchange columns (2,6,25,34).
2) The use of adsorbents such as histidine, histamine, polymyxin B, nant proteins used either in vitro or in vivo.
Endotoxin is a lipopolysaccharide (LPS) forming an and poly-L-lysine to facilitate adsorption of endotoxin to matrix by electrostatic and hydrophobic interactions. integral part of the Gram-negative bacteria outer membrane responsible for bacterial organization and stability Even though the interaction between adsorbent and endotoxin is selective, the multiple rounds of the treatment (47). In vivo exposure to endotoxin-contaminated products triggers adverse reactions such as rising body temand repeated protein dilutions decrease product recovery (3).
3) The use of Triton X-114, which is an efficient perature, activation of coagulation cascade, modification of hemodynamics, and septic shock (26). Endotoxin can compound for endotoxin removal from recombinant proteins (1, 23) , and it can be used either in a phase separasignificantly modify interpretation of in vitro experiments (11) . Therefore, its removal or deactivation is a tion method (23) or in washing solutions for affinity chromatography columns (37) . However, traces of the critical step in production of E. coli-generated recombinant proteins. dilutions tested were properly spiked to confirm results.
Endotoxin Deactivation MATERIALS AND METHODS
The pH of the recombinant protein solution or monoProtein Generation and Purification clonal antibody clone 5c8 was adjusted to acidic conditions as follows: the protein was purified as described Small frozen stock aliquot of E. coli (BL21) transformed with plasmid coding for protein of interest was above; the concentration was corrected to 0.5 mg/ml and assessed utilizing colorimetric Protein-Assay (Bio-Rad). inoculated into 100 ml of LB/Amp medium supplemented with antibiotics and incubated for 5 h at 37°C
The pH of 5 ml protein solution was adjusted dropwise with constant stirring using 1 M HCl and monitored with continuous agitation. The 100-ml culture was transferred to 1 L of LB/Amp media and grown for additional with pH meter. After the protein reached desired acidic pH it was incubated at room temperature for 20 min. At 16 h under the same conditions. The resulting bacterial culture was centrifuged; the pellet was washed once the end of incubation the pH was slowly returned to its original value with 1 M NaOH and the protein solution with PBS and resuspended in 30 ml of PBS supplemented with protease inhibitors (Complete, EDTA free; was filtered by passage through the 0.2-µm Acrodisc syringe filter. The concentration of the recovered protein Roche) and 20 mM imidazole. The suspension was sonicated in three repetitions of 21 s, 50% amplitude, and was measured by colorimetric protein assay kit (BioRad) and the protein was subjected to functional studies. 5c8, 1-min cool off period (Fisher Scientific Sonic Dismembrator, Model 500). The resulting bacterial extract was the hybridoma clone against CD154 (CD40 ligand), was subjected to the above-described procedure twice at pH centrifuged 45 min at 12,000 rpm and the supernatant was loaded on Ni-agarose column (Qiagen) previously 5. All tubes were purchased endotoxin free (Corning, Falcon conical tubes or borosilicate pyrogen-free test equilibrated with 20 mM imidazole buffer. The protein bound to the column was washed with 20 and 30 mM tubes; Lonza, Cat. #N207). The pH electrode was presoaked in 0.1 M HCl and washed extensively with pyroimidazole buffers and eluted with 100 mM imidazole buffer. The eluted protein was desalted on PD-10 colgene-free water before each use. umn (Amersham-Pharmacia). Fractions were monitored Assessment of Endotoxin Activity In Vivo with colorimetric protein assay kit (Bio-Rad Cat. #500-0006) and quantified by spectrophotometer (BeckmanPyrogenic tests were performed with two groups of three male rabbits each, weighing between 2.2 and 3.2 DU 640) at 595 nm wavelength.
For in vivo experiments, the protein solution was kg. The rectal probe was inserted and each animal was allowed to acclimate to its restrained position for 1 h. sterilized by passage through the 0.2-µm syringe filters (Acrodisc HT Tuffryn Membrane Low Protein Binding
Four temperature readings at 30-min intervals were recorded and the average of all four readings was regisNon-pyrogenic).
Recombinant proteins used in this study were: murine tered as a base line temperature. The animals were than infused for 4 min via the marginal ear vein with preheme oxigenase 1 (HO-1), cell-permeable mouse TAT heme oxigenase 1 (TAT-HO-1) (37), human neurogwarmed protein solution (37°C) and appropriate volume per kilogram (3.5-4 ml/kg) with no significant differlobin (Ngb) (27) , cell-permeable human TAT-transcription factor PDX-1 (TAT PDX-1), and β-galactosidase ences in solution volume between groups. The first group (group 1) received solution with TAT-HO-1 pro- (41) . To one of the preparations of TAT-HO-1, 6 M urea solution was added to investigate if urea has a negative tein (38) that underwent endotoxin deactivation at pH 5 with the final endotoxin level of 0.3 EU/ml measured effect on the described endotoxin decontamination method. HO-1 and TAT-HO-1 proteins were chosen for by LAL. The second group (group 2) received the TAT-HO-1 preparation that was not subjected to endotoxin lowering the pH of the protein to acidic range. We have verified this method with a number of recombinant protreatment and contained 20 EU/ml, similar amounts of protein were injected in both groups. Prior to infusion teins, each with a different isoelectric point (pI). The experiments were performed with a variety of pH values the samples were equally diluted. The dilutions were made to prevent occurrence of the lethal pyrogenicity in (Table 1) . Overall, we detected a decrease in endotoxin activity at acidic pH below the respective protein pI. The the nontreated group (group 2). All pyrogenic in vivo testing was done by NAMSA (Irvine, CA, USA), a fully endotoxin activity was not significantly decreased at the basic pH range (data not shown). The subsequent protein accredited company that performs in vivo pyrogen assessments. After the infusion the temperatures were rerecovery seems to depend on the protein type. For example, even though more than 99% of endotoxin was deaccorded at 30-min intervals for 3 h. All procedures were conducted in compliance with good laboratory practice, tivated in HO-1, TAT-HO-1, Ngb, and TAT-PDX the recovery of each protein varied from 90.4%, 72.9%, SO 17025 and met nonpyrogenic requirements for United States Pharmacopeia (USP).
60.8%, to 46.8%, respectively. We have compared effectiveness of endotoxin deactivation under acidic pH conPeripheral Blood Lymphocytes Activation ditions using either plastic containers (Corning or Falcon Peripheral blood lymphocytes (PBL) from the freshly conical) or borosilicate pyrogen-free test tubes. As long drawn blood of healthy cynomolgus monkey (Mannas the acidic conditions were upheld the material of heimer, Miami FL) were isolated on Ficoll-Hypaque which the vessel was made had no effect on the final (Sigma Chemical Co., St. Louis, MO) following manuresults (data not shown). At neutral pH, proteins in plasfacturer' instructions. The purified PBLs (10 × 10 6 /ml) tic containers showed slow endotoxin decrease over time were cultured at 37°C in a humidified atmosphere of 5% (Tables 1 and 2) . CO 2 for 6 h in RPMI-1640 medium (Gibco-BRL, NY)
Once the preliminary screening of various proteins supplemented with 10 ng/ml of PMA (Sigma Chemical was completed, we studied the reproducibility of this Co.), 10 mg/ml of PHA (Sigma Chemical Co.), 10%
procedure and purified 10 TAT-HO-1 preparations at pH heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml 5 and 12 preparations at pH 6 (Table 2) . Endotoxin was streptomycin, 10 nM sodium pyruvate, 2 mM L-glutaefficiently deactivated at pH 5; the remaining activity mine, 0.1 mM nonessential amino acids, and 1× vitawas negligible at 0.31 ± 0.11% EU/mg (n = 10; p = mins (all from Gibco-BRL, NY). After T-cell activation, 0.00018). On average, the protein recovery was 64.45 ± cells were washed twice with PBS (Gibco-BRL, NY) 3.87%. The endotoxin activity varies greatly from prepaand immunostained.
ration to preparation. The treated TAT-HO-1 did not The 5c8 is a protein A purified monoclonal antibody lose its biological activity, assessed as the capability to that was specially generated by an original 5C8 hybridprotect the insulinoma cells βTC3 from death induced oma cell line obtained from ATCC (Cat. #HB-10916, by a combination of 10 µg/ml cyclohexamide and 4000 Lot #222225) through Rockland (www.rockland-inc. U/ml TNF-α (38) . There was virtually no difference in com) with Code #CUST22M and Lot #17544C.Clone function of treated and untreated protein (data not shown). 5c8 anti-CD154 is being used extensively in vivo and in Efficient Endotoxin Deactivation in the Presence vitro for CD40 signaling research at the Diabetes Reof Urea search Institute and therefore was a logical choice for our experiments.
Because urea is frequently used in recombinant protein purification protocols, we tested if it has adverse Statistical Analysis effect on our method of endotoxin deactivation. In ureaResults from protein acidification at pH 5 and 6 were free recombinant protein, the endotoxin activity was analyzed using Wilcoxon signed rank test for paired, reduced from 8107.55 to 5.57 EU/mg (99.9% activity nonparametric samples, with 95% confidence intervals. reduction); in the presence of 6 M urea the final concenEndotoxin activity and binding efficiency of anti-CD154 tration of remaining activity was 49.62 EU/mg (99.4% before and after acidification were analyzed using twoactivity reduction). The protein recovery was similar for tailed Student t-test with a value of p < 0.05 considered both conditions 70.72 ± 7.48% and 73.71 ± 8.27%, restatistically significant. spectively.
RESULTS

In Vivo Pyrogenic Determination Endotoxin Activity Decreases After Acidic
The in vivo pyrogen assay with rabbits confirmed the pH Treatment results obtained with LAL in vitro assays in regards to endotoxin deactivation. Figure 1 demonstrates untreated Initially, we have observed that the endotoxin activity in recombinant proteins was dramatically reduced by TAT-HO1 protein with high endotoxin activity as fully pyrogenic while the treated TAT-HO1 protein with very DISCUSSION low endotoxin activity shows no pyrogenic response, which correlates the in vivo studies with the in vitro With the progress of genomics and proteomics in recent years, the production of recombinant therapeutic LAL based results.
proteins and peptides has increased significantly. Thera-
Effect of Endotoxin Deactivation on Monoclonal
peutic proteins and peptides have been delivered to sevAntibody Produced by Hybridoma eral cell types or tissues such as brain (19, 29, 32, 36) , muscle (5,8,49,50), heart (3,15), eye lens epithelial cells Low levels of endotoxin activity (0.51 EU/mg; Table  3 ) were found in proteins produced in sources other than (28), and into living organisms (43). The recombinant proteins are considered for use in cell transplantation as bacteria, such as monoclonal antibody produced by hybridoma clone 5c8 (ATCC, Manassas, VA; Cat. #HB-well (22,33). Furthermore, human cells were successfully transduced with artificial transcriptional regulatory 10916). The monoclonal antibody 5c8 is a clone directed against human CD154 (CD40 ligand) (20) . After two proteins, such as zinc-finger transcription factors (35). Recombinant proteins with antiapoptotic/necrotic proprounds of acidic treatment at pH 5 the activity levels of endotoxin were no longer detectible by our method of erties were delivered to islets postisolation and prior to transplantation to protect them from stress. The transassessment. The loss of protein was minimal (Table 3) . Activity of the antibody measured by the binding capaduction reduced apoptosis and necrosis of transplanted islets (13, 33) . Recent reports indicate that delivery of bility of the 5c8 to in vitro-activated PBLs expressing CD154 showed no significant difference between treated recombinant transcription factor PDX-1 has a potential to treat diabetes (21) . Recombinant proteins have been and untreated samples (Table 3, Fig. 2) . used to engineer stem cells or progenitor cells in order pH, the endotoxin activity of most recombinant proteins has been dramatically reduced as assessed by in vitro to differentiate them into cell types such as insulin producing cells (β-cells) (10, 31, 46, 51) , hematopoietic cells and in vivo assays. We applied the method to different recombinant proteins. In order to optimize efficiency of (24), and neurons (17, 44) , which could be used to treat diabetes, leukemia, and diseases of nerves system, reendotoxin deactivation and protein recovery, it was necessary to test treatments with various acidic pH for each spectively. Recombinant proteins have been used to reprogram induced pluripotent stem cells as well (4,52).
target protein (Table 1) . Optimal endotoxin deactivation was observed at pH below the isoelectric point of the Most of these proteins are produced in bacteria and endotoxin deactivation should be a mandatory step of the treated protein (Table 1) . The finding that endotoxin activity may be dramatipurification.
We have found that after short incubation at acidic cally reduced in protein preparations merely by acidic pH treatment, without any further processing, was surprising. Biologically active endotoxin, in the form of micellar aggregates (28), is capable of interacting with The decrease in pH is believed to aid the dissociation method, which brought the endotoxin activity below the detection levels (Table 3) . of endotoxin-protein aggregates for subsequent separation using the methods described above. However, our
In conclusion, this study describes a simple and inexpensive procedure to reduce endotoxin activity in prostudies show that endotoxin is no longer active after acidic pH treatment and therefore no further removal is teins able to withstand acidic pH treatment. Because the previous endotoxin elimination technique is a complirequired. Interestingly, examples of endotoxin conformations that are inactive have been previously described cated step in protein purification it could be worth to test our simple method before embarking on more complex (12, 40, 45) . Conformation changes of endotoxin aggregates are also known to occur at different pH ranges (7) .
procedures. Therefore, we speculate that the acidic treatment irre-
ACKNOWLEDGMENTS: This work was supported by a grant from the National Institutes of Health (DK-59993 to R.L.P.).
versibly changes the endotoxin conformation, which biophysical and biochemical studies will be necessary to shed the light on the mechanism responsible for the REFERENCES inhibition of endotoxin activity after acidic treatment. 
